Claims for Patent: 10,251,906

Summary for Patent: 10,251,906

Title:	Compositions and methods for inducing apoptosis
Abstract:	In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Inventor(s):	Kopecek; Jindrich Henry (Salt Lake City, UT), Yang; Jiyuan (Salt Lake City, UT), Chu; Te-Wei (Salt Lake City, UT)
Assignee:	UNIVERSITY OF UTAH RESEARCH FOUNDATION (Salt Lake City, GA)
Application Number:	14/773,791
Patent Claims:	1. A method of inducing apoptosis in CD20 positive human cells, the method comprising: (i) contacting a population of human cells comprising CD20 positive cells with a first complex comprising a targeting moiety and a morpholino wherein the targeting moiety is an anti-CD20 antibody or an anti-CD20 Fab' fragment; and (ii) contacting the population of human cells with a second complex comprising a copolymer carrier and one or more morpholinos; wherein the morpholino of the first complex is 5' GAG TAA GCC AAG GAG AAT CAA TAT A 3' (SEQ ID NO:25) and wherein the one or more morpholinos of the second complex are 5' TAT ATT GAT TCT CCT TGG CTT ACT C 3' (SEQ ID NO:26), wherein the contacting of the human cells with the first complex and the second complex induces apoptosis of the CD20 positive human cells. 2. The method of claim 1, further comprising repeating step (i) and step (ii). 3. The method of claim 1, further comprising (iii) confirming apoptosis of the human cells. 4. The method of claim 1, wherein the cells are B-cells. 5. The method of claim 1, wherein the cells are in a subject. 6. The method of claim 5, wherein the subject has non-Hodgkin's lymphoma. 7. The method of claim 1, wherein the Fab' fragment is derived from an anti-CD20 receptor antibody. 8. The method of claim 7, wherein the anti-CD20 antibody is 1F5, rituximab, tositumomab, ibritumomab, ofatumumab, veltuzumab, ocrelizumab, ocaratuzumab, obinutuzumab, PRO131921, BCD-020, IBI-301, ublituximab, or BLX-301. 9. A method of inducing apoptosis in CD20 positive cells, the method comprising: contacting a population of human cells comprising CD20 positive cells with a composition comprising a first complex comprising a targeting moiety and a morpholino and a second complex comprising a complex comprising a copolymer carrier and one or more morpholinos, wherein the targeting moiety is an anti-CD20 antibody or anti-CD20 Fab' fragment, wherein the morpholino of the first complex is 5' GAG TAA GCC AAG GAG AAT CAA TAT A 3' (SEQ ID NO:25) and wherein the one or more morpholinos of the second complex are 5' TAT ATT GAT TCT CCT TGG CTT ACT C 3' (SEQ ID NO:26), wherein the contacting of the human cells with the composition induces apoptosis of the CD20 positive cells. 10. The method of claim 9, further comprising repeating the contacting of the human cells with the composition. 11. The method of claim 9, wherein the cells are B-cells. 12. The method of claim 9, wherein the cells are in a subject. 13. The method of claim 12, wherein the subject has non-Hodgkin's lymphoma. 14. The method of claim 9, wherein the anti-CD20 receptor antibody is 1F5, rituximab, tositumomab, ibritumomab, ofatumumab, veltuzumab, ocrelizumab, ocaratuzumab, obinutuzumab, PRO131921, BCD-020, IBI-301, ublituximab, or BLX-301.

Details for Patent 10,251,906

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-03-12
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10/26/2009		2033-03-12
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	04/01/2011		2033-03-12
Novartis Pharmaceuticals Corporation	KESIMPTA	ofatumumab	Injection	125326	08/20/2020		2033-03-12